Johnson & Johnson reported on Apr. 15 that it achieved $24.1 billion in sales for the first quarter, marking a "modest" beat as the company aims for $100 billion in revenue by 2026. The announcement comes as Johnson & Johnson is the first major biopharmaceutical company to release its quarterly results, with more companies expected to follow soon.
The start of earnings season is significant for investors, especially amid a surge of mergers and acquisitions across the biopharma sector. This wave of deals is expected to be a central topic during upcoming investor calls from other major firms such as Novo Nordisk and Eli Lilly. Additionally, initial public offerings are on the rise, with Kailera Therapeutics reportedly seeking to raise up to $533 million.
In regulatory news, Replimune was denied approval by the Food and Drug Administration (FDA) for its advanced melanoma therapy RP1 for a second time. The FDA requested an additional Phase 3 trial—a step that CEO Sushil Patel said last week “will not be viable.” Analysts say that recent changes at the FDA, including making complete response letters public, have led to greater accountability within the agency.
Transparency and flexibility have been key themes at the FDA this year. While there have been cases where sponsors believe guidance has shifted unexpectedly, two companies—Rezolute and CERo Therapeutics—recently praised their interactions with FDA reviewers as “collaborative” and “curious.”
Ahead of this weekend’s American Association for Cancer Research annual meeting, several companies released positive data on new therapies targeting various cancers. Revolution Medicines reported that its therapy daraxonrasib doubled survival rates in pancreatic cancer patients—a disease with only a 13% five-year survival rate—while Allogene, IDEAYA Biosciences, and Servier also announced encouraging results.
